Placebo to match LY3650150 clinical trials

J2T-MC-KGBI/DRM06-AD13: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic Dermatitis

This study is testing a new medicine called lebrikizumab for children and teenagers aged 6 months to under 18 years with moderate to severe eczema. We want to see if it helps improve their skin and is safe compared to a dummy medicine.